GeoVax Secures Patent for Multi-Antigen COVID-19 Vaccine Technology

The U.S. Patent and Trademark Office has issued a Notice of Allowance for GeoVax Labs' patent application covering recombinant Modified Vaccinia Ankara viral vectors encoding multiple SARS-CoV-2 proteins. The allowed claims broadly protect vaccine constructs designed to generate virus-like particles that present Spike, Membrane, and Envelope antigens in their natural conformation. This multi-antigen approach mimics the natural virus structure and is engineered to induce both antibody and T-cell responses for durable and broad immune protection against current and emerging variants.

The patent coverage includes ancestral strain sequences and variant-associated mutations such as K417N/T, E484K, and N501Y, addressing concerns about immune escape as the virus continues to evolve. David Dodd, GeoVax President and CEO, emphasized that this represents a significant strengthening of the company's intellectual property estate protecting next-generation COVID-19 vaccines. Unlike single-antigen vaccines, these MVA-based multi-antigen constructs are specifically designed to elicit broad-spectrum protection that remains effective despite viral evolution.

The newly allowed patent covers constructs central to GeoVax's CM01 and CM02 vaccine candidates, which express multiple SARS-CoV-2 proteins to generate virus-like particles in vaccinated individuals. These vaccine designs aim to provide comprehensive protection by engaging both arms of the immune system and countering immune escape by new viral variants. Combined with GEO-CM04S1, which is advancing through Phase 2 clinical trials in immunocompromised and healthy populations, this portfolio positions GeoVax as a leader in next-generation COVID-19 vaccine innovation.

The technology represents a differentiated approach from single-antigen vaccines such as mRNA vaccines, focusing on multi-antigen presentation that more closely resembles natural infection. This could potentially address limitations of current vaccines in providing durable protection against rapidly evolving SARS-CoV-2 variants. The patent allowance strengthens GeoVax's intellectual property position as the company continues developing novel vaccines against infectious diseases and cancer therapies. For more information about the company's technologies and clinical programs, visit https://www.geovax.com.